In the 21st century, where technology, social networks and communications in filtrate all social processes, natural events have been relegated to a secondary role. Birth, death and sickness have acquired a new value and collective concept.

Synthetic oxytocin (SynOT) (Pitocin®, Syntocinon®) is a drug that is used regularly to prevent and to care post partum haemorrhage in childbirth. On the other hand oxytocin (OT) is also an important mediator of life processes; it has been defined “the Great Facilitator of Life”. OT may affect behaviors and physiology to facilitate the propagation of species. Previous studies suggest there is likely to be a high level of OT in the first feed of colostrum after a woman has received SynOT for this purpose. This apparently transient exposure could have direct effects on the immunological development of the infant gut as, at this stage of life, the gut is particularly sensitive to OT and is pivotal in the development of the infant's immune system. The complexities of the developing immune system are only just being exposed, however, the notion that many autoimmune diseases may develop from this period is increasingly well accepted. From an epigenetic point of view, the establishment of a suitable commensal biome and exposure to appropriate antigens is essential in this postnatal period. Furthermore, in the perinatal period, there are times of particular sensitivity in which the correct receptor/hormone ratio develops. If the initial ratio is incorrect, the receptor/hormone ratio may be damaged throughout the whole life of the individual, this is the called ‘Faulty Perinatal Hormonal Imprinting'. Another mechanism through which this process could take place is genomic imprinting. These complex developmental processes are critical to the ongoing health of the infant and are likely to be affected by the amount of SynOT introduced in the first feed. For these and other reasons it is important to evaluate different drugs to reduce postpartum haemorrhage in low-risk women. With this goal in mind we are currently testing tranexamic acid for post partum haemorrhage prophylaxis. This review explains the main reasons why, based on the principle of prudence, it is important to evaluate different drugs from oxytocin for prophylaxis of postpartum hemorrhage (PPH).This article presents conceptual arguments and empirical facts in support of this hypothesis.

Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive age. Pathophysiological mechanisms include insulin resistance, which contributes to the development of hyperandrogenemia. Modification of insulin resistance by insulin sensitizers (eg metformin) is one of the therapeutic options for treating PCOS. Metformin improves menstrual cycle, induces fertility, reduces abortions and improvesinsulin sensitivity and androgen and lipid metabolism. Although metformin is aninteresting treatment modality in PCOS women before and during pregnancy, according to the U.S. Food and Drug Administration, it is classified in Class B. Despite the lack of randomized and double-blind clinical trials, treatment is recommended to be safe, effective and non-pathological based on a comparison of the incidence of abortion before and after treatment with metformin.

Statins are HMG-CoA reductase inhibitors. They are used as the first-hand medications for treatment of hypercholesterolemia. Statins have also anti-inflammatory and antimicrobial effects. According to literature, during the years 1999-2017 the research on atorvastatin with liquid chromatography has increased to 481 papers. However, atorvastatin studies with gas chromatography and capillary electrophoresis has both been reported in 15 papers during 2006-2017. The present paper compiles the most recent studies of these studies on atorvastatin made with chromatographic and electro aided techniques.